Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381067 | 0.89 | PLAU (0.31) | PLAUP2RX3ALDH1A1MAPT | |
| SCHEMBL4380967 | 0.84 | L3MBTL1 (0.36) | PLAUP2RX3L3MBTL1ALDH1A1MAPT | |
| SCHEMBL4379675 | 0.83 | ALDH1A1 (0.39) | P2RX3ADORA1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL4386891 | 0.80 | EGFR (0.41) | ALDH1A1LMNA | |
| SCHEMBL4379960 | 0.79 | ALDH1A1 (0.39) | P2RX3L3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL4382100 | 0.79 | LMNA (0.41) | L3MBTL1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4386738 | 0.78 | ALDH1A1 (0.38) | ALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL4385713 | 0.76 | POLB (0.46) | L3MBTL1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL4387756 | 0.75 | ALDH1A1 (0.34) | PLAUP2RX3L3MBTL1ALDH1A1LMNA | |
| SCHEMBL4379817 | 0.73 | EGFR (0.40) | L3MBTL1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | PLAU 4884/4885P2RX3 2132/4885ADORA1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.